Precision Biosciences

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acceptable Toler ability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS) , and No Grade ≥ 3 Neurotoxicity (ICANS)

Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)

DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020.

Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Eli Lilly

INDIANAPOLIS, and DURHAM, N.C., Nov. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS® genome editing platform for the...

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

Shares of Precision BioSciences (NASDAQ:DTIL) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 21.95% year over year to ($0.50), which beat the estimate of ($0.66).

Precision BioSciences: Q3 Earnings Insights

Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors

Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update

Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Precision BioSciences (DTIL) Q3 Earnings Expected to Decline

DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that it will publish financial results for the third quarter of 2020 and provide a business update on Tuesday, November 10, 2020.

Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020

Precision BioSciences, Inc. is a life sciences company focused on utilizing its ARCUS genome editing platform to primarily treat human diseases and secondarily to provide food/agricultural solutions. Precision Bio has 2 collaborations and a pipeline of 8 therapeutics (3 clinical) and 4 food-based products. Clinical therapeutics target a market worth $40.7B covering NHL, ALL, CLL/SLL, and MM.

Precision Bio: 2020 Is Not Looking Great With 2 Terminated Partnerships And Cash Down -30% To $127M.

PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings

Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents

DURHAM, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alex Kelly has been appointed to the newly created position of Chief Corporate Affairs Officer. In this role, Alex joins the senior leadership team, reporting to Matt Kane, Chief Executive Officer at Precision and will oversee all investor relations and corporate communications.

Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer

DURHAM, N.C., Sept.  28, 2020  (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced its participation in the following upcoming virtual investor conferences:

Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October

Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Targeted CAR T Cell Product Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Targeted CAR T Cell Product

Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

A key update from the U.S. Food and Drug Administration (FDA) boosted Precision BioSciences Inc.

Why This FDA Update Is a Huge Step Forward for Precision BioSciences

DURHAM, N.C., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PBCAR269A for the treatment of relapsed/refractory multiple myeloma. This is the company’s second allogeneic chimeric antigen receptor (CAR T) cell therapy to receive Fast Tack Designation for which the FDA previously granted Orphan Drug Designation.

Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma

DURHAM, N.C., Sept.  02, 2020  (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced its participation in the following upcoming investor conferences:

Precision BioSciences to Present at Upcoming Virtual Investor Conferences in September

DURHAM, N.C., Aug.  19, 2020  (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Precision for PBCAR0191, the company’s lead investigational allogeneic chimeric antigen receptor (CAR T) cell therapy for the treatment of advanced B-cell precursor acute lymphoblastic leukemia (B-ALL).

Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy

Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma

Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update

Earnings Preview: Precision BioSciences (DTIL) Q2 Earnings Expected to Decline

DURHAM, N.C., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform today announced it will report financial results for the second quarter of 2020 on August 13, 2020.

Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor Conferences

DURHAM, N.C., July  06, 2020  (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that the Company will regain full rights and all data it generated for the in vivo chronic hepatitis B virus (HBV) program developed under its 2018 collaboration agreement with Gilead Sciences.

Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program

-PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic –

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma

Shares of Precision BioSciences (NASDAQ:DTIL) rose 8.2% in pre-market trading after the company reported Q1 results.

Precision BioSciences: Q1 Earnings Insights

Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL

News for Precision Biosciences Stock (DTIL)